Cancer is being reinterpreted in the light of recent discoveries related to the histone code and the dynamic nature of epigenetic regulation and control of gene programs during development, as well as insights gained from whole cancer genome sequencing. Somatic mutations in or deregulated expression of genes that encode chromatin-modifying enzymes are being identified with high frequency. Nowhere is this more relevant than in pediatric embryonal solid tumors. A picture is emerging that shows that classic genetic alterations associated with these tumors ultimately converge on the epigenome to dysregulate developmental programs. In this review, we relate how alterations in components of the transcriptional machinery and chromatin modifier genes contribute to the initiation and progression of pediatric solid tumors. We also discuss how dramatic progress in our understanding of the fundamental mechanisms that contribute to epigenetic deregulation in cancer is providing novel avenues for targeted cancer therapy. Clin Cancer Res; 18(10); 2768–79. ©2012 AACR.

Cancer is a developmental disease, and the hijacking of biologic processes that are central to normal embryonic development is an essential feature of human malignancy. Nowhere is this more apparent than in pediatric tumors, where disruptions to normal development are believed to underlie the genesis of many (if not all) childhood tumors (1). Normal mammalian development is a precisely orchestrated process that results in the creation of hundreds of differentiated cell types from a single pluripotent stem cell. This process of progressive lineage specification and cellular differentiation is dependent on epigenetic regulation, which directs heritable changes in gene expression independently of DNA sequence changes (2–4). In eukaryotic cells, DNA is wrapped around core histone proteins and packaged into compact chromatin structures termed nucleosomes (Fig. 1). Epigenetic regulation of gene expression is predominantly controlled by covalent modifications of histones, changes to nucleosome conformation and position (nucleosome remodeling), and DNA methylation (Figs. 1 and 2). In this article, we review normal epigenetic regulation and discuss how disruptions to the epigenetic machinery contribute to the initiation and progression of pediatric solid tumors. In addition, we discuss how an advanced understanding of epigenetic regulatory mechanisms is providing novel avenues for targeted cancer therapy.

Figure 1.

Higher-order complexity of DNA. To achieve the required nuclear compactness, eukaryotic DNA is wrapped around core histone proteins (histone octamers) and packaged into compact chromatin structures termed nucleosomes. Epigenetic regulation of gene expression is predominantly controlled by covalent modifications to histones (on histone tails). These posttranslational modifications signal the recruitment of protein complexes that (i) more tightly package the nucleosomes, causing condensed chromatin (referred to as heterochromatin; heterochromatin is devoid of gene transcription); (ii) remodel the nucleosomes, leading to more loosely or irregularly spaced nucleosomes (referred to as euchromatin; regulated gene transcription takes place in euchromatin regions); and (iii) recruit proteins that are responsible for DNA methylation. Inset: Modifications to histone tails. In particular, methylation of lysine residues 9 and 27 on histone 3 (H3K9me2, H3K9me3, and H3K27me3) and ubiquitination of histone 2A (H2AUb) are associated with a more compact heterochromatin structure and gene silencing (6). The activity of methyltransferases is countered by proteins with demethylase activity. Lysines may also be acetylated by acetyltransferases, such as GCN5/PCAF and CBP/p300, and acetylated lysines typically favor gene transcription. A series of HDACs (HDAC1–11) deacetylate lysine residues, and increased activity or levels of these proteins is associated with gene silencing. Proteins involved in these processes are explained in more detail in Fig. 2. Histone modifications associated with silencing and the proteins that mediate them are denoted in red, and those associated with gene activation are denoted in green.

Figure 1.

Higher-order complexity of DNA. To achieve the required nuclear compactness, eukaryotic DNA is wrapped around core histone proteins (histone octamers) and packaged into compact chromatin structures termed nucleosomes. Epigenetic regulation of gene expression is predominantly controlled by covalent modifications to histones (on histone tails). These posttranslational modifications signal the recruitment of protein complexes that (i) more tightly package the nucleosomes, causing condensed chromatin (referred to as heterochromatin; heterochromatin is devoid of gene transcription); (ii) remodel the nucleosomes, leading to more loosely or irregularly spaced nucleosomes (referred to as euchromatin; regulated gene transcription takes place in euchromatin regions); and (iii) recruit proteins that are responsible for DNA methylation. Inset: Modifications to histone tails. In particular, methylation of lysine residues 9 and 27 on histone 3 (H3K9me2, H3K9me3, and H3K27me3) and ubiquitination of histone 2A (H2AUb) are associated with a more compact heterochromatin structure and gene silencing (6). The activity of methyltransferases is countered by proteins with demethylase activity. Lysines may also be acetylated by acetyltransferases, such as GCN5/PCAF and CBP/p300, and acetylated lysines typically favor gene transcription. A series of HDACs (HDAC1–11) deacetylate lysine residues, and increased activity or levels of these proteins is associated with gene silencing. Proteins involved in these processes are explained in more detail in Fig. 2. Histone modifications associated with silencing and the proteins that mediate them are denoted in red, and those associated with gene activation are denoted in green.

Close modal
Figure 2.

Protein modifications and complexes that regulate higher-order chromatin conformation. A, PcG-protein complexes. The PRC2 protein EZH2 is the key effector of PRC2 action, catalyzing trimethylation of H3K27 [H3K27me3 (7, 8)]. HDACs also bind the PRC2 complex, decreasing acetylation of H3K27 and favoring its methylation, and inhibiting gene transcription. In contrast, inhibitors of histone deacetylases (e.g., vorinostat and romidepsin) would be expected to counteract this activity, resulting in increased acetylation at these loci, favoring gene expression. For example, at steady state, EZH2 mediates increased H3K27me3 at the CASZ1 tumor suppressor gene and loss of gene transcription in neuroblastoma, and romidepsin (depsipeptide) treatment leads to increased H3K27Ac and increased gene transcription at this locus (57). PRC2 is targeted to DNA by JARID2, which binds GC-containing DNA regions. PRC1 in turn mono-ubiquitinates H2A, a task that is achieved by the PRC1 protein BMI-1 in cooperation with the E3 ubiquitin ligase RING1B (7, 8). In contrast, acetylation of lysine residues on histones 3 and 4 (H3K, H4K) and methylation of H3K residue 4 (H3K4me3) promote an open euchromatin state and active transcription. B, nucleosome remodeling. The ATP-dependent chromatin remodeling complexes are a family of proteins (SWI/SNF, ISWI, NURD/MI-2/CHD, and INO80) characterized by common DExx and HELICc domains. These chromatin-remodeling complexes use energy-dependent mechanisms to move the DNA around the histone octamer and also alter histone octamer composition. Most significantly, the SWI/SNF complex has been shown to play essential roles in regulating nucleosome remodeling, contributing to both the activation (left, denoted in green) and repression (right, denoted in red) of gene expression programs in a context-dependent manner (17). During lineage-specific differentiation, the SWI/SNF complex cooperates with transcription factors to promote the activation of differentiation genes and silencing of proliferation genes. C, DNA methylation. Methylation of CpG islands located in proximity to transcription initiation is associated with heritable silencing (denoted in red) of gene expression (gene OFF) and is responsible for physiologic processes that depend on permanent gene silencing, such as X-chromosome inactivation and gene imprinting (11). DNA methylation may be mediated by transcription factor– or PcG-mediated recruitment of DNMTs to specific gene loci. D, DNA demethylation. More recent studies have identified DNA demethylases (TET1,2) that hydroxylate 5-mC in CpG dinucleotides to 5-hC. Evidence suggests that TET enzymes are capable of iterative oxidation on substrates to 5-fC or 5-caC (23, 24). This leads to substrates upon which base excision repair mechanisms mediated by TDG excise a modified C and replace it with an unmodified C, allowing for rapid reactivation (gene ON) of previously silenced genes (24). 5-caC, 5-carboxymethylcytosine; 5-fC, 5-formylmethylcytosine; 5-hC, 5-hydroxymethylcytosine; 5-mC, 5-methylcytosine; TDG, thymine-DNA glycosylase.

Figure 2.

Protein modifications and complexes that regulate higher-order chromatin conformation. A, PcG-protein complexes. The PRC2 protein EZH2 is the key effector of PRC2 action, catalyzing trimethylation of H3K27 [H3K27me3 (7, 8)]. HDACs also bind the PRC2 complex, decreasing acetylation of H3K27 and favoring its methylation, and inhibiting gene transcription. In contrast, inhibitors of histone deacetylases (e.g., vorinostat and romidepsin) would be expected to counteract this activity, resulting in increased acetylation at these loci, favoring gene expression. For example, at steady state, EZH2 mediates increased H3K27me3 at the CASZ1 tumor suppressor gene and loss of gene transcription in neuroblastoma, and romidepsin (depsipeptide) treatment leads to increased H3K27Ac and increased gene transcription at this locus (57). PRC2 is targeted to DNA by JARID2, which binds GC-containing DNA regions. PRC1 in turn mono-ubiquitinates H2A, a task that is achieved by the PRC1 protein BMI-1 in cooperation with the E3 ubiquitin ligase RING1B (7, 8). In contrast, acetylation of lysine residues on histones 3 and 4 (H3K, H4K) and methylation of H3K residue 4 (H3K4me3) promote an open euchromatin state and active transcription. B, nucleosome remodeling. The ATP-dependent chromatin remodeling complexes are a family of proteins (SWI/SNF, ISWI, NURD/MI-2/CHD, and INO80) characterized by common DExx and HELICc domains. These chromatin-remodeling complexes use energy-dependent mechanisms to move the DNA around the histone octamer and also alter histone octamer composition. Most significantly, the SWI/SNF complex has been shown to play essential roles in regulating nucleosome remodeling, contributing to both the activation (left, denoted in green) and repression (right, denoted in red) of gene expression programs in a context-dependent manner (17). During lineage-specific differentiation, the SWI/SNF complex cooperates with transcription factors to promote the activation of differentiation genes and silencing of proliferation genes. C, DNA methylation. Methylation of CpG islands located in proximity to transcription initiation is associated with heritable silencing (denoted in red) of gene expression (gene OFF) and is responsible for physiologic processes that depend on permanent gene silencing, such as X-chromosome inactivation and gene imprinting (11). DNA methylation may be mediated by transcription factor– or PcG-mediated recruitment of DNMTs to specific gene loci. D, DNA demethylation. More recent studies have identified DNA demethylases (TET1,2) that hydroxylate 5-mC in CpG dinucleotides to 5-hC. Evidence suggests that TET enzymes are capable of iterative oxidation on substrates to 5-fC or 5-caC (23, 24). This leads to substrates upon which base excision repair mechanisms mediated by TDG excise a modified C and replace it with an unmodified C, allowing for rapid reactivation (gene ON) of previously silenced genes (24). 5-caC, 5-carboxymethylcytosine; 5-fC, 5-formylmethylcytosine; 5-hC, 5-hydroxymethylcytosine; 5-mC, 5-methylcytosine; TDG, thymine-DNA glycosylase.

Close modal

Histone modifications

Histone modifications such as acetylation, methylation, and ubiquitination lead to changes in chromatin structure that determine the accessibility of DNA to transcription factors (Fig. 1; refs. 5, 6). Histone acetylation and methylation are dynamically regulated by the competing actions of histone acetyltransferases and histone deacetylases (HDAC), and histone methyltransferases (HMT) and histone demethylases, respectively (6). Repressive histone modifications are largely driven by the action of Polycomb group (PcG) proteins (7, 8). PcG proteins function as multiprotein complexes (PRC1 and PRC2) that act cooperatively to silence transcription, mainly by trimethylating lysine residue 27 on histone 3 (H3K27me3). In stem cells, PcG proteins maintain self-renewal and pluripotency by repressing differentiation genes (2, 8). PcG proteins also interact with DNA methyltransferases (DNMT) to induce permanent transcriptional silencing by enabling DNA methylation (Fig. 2A and C; refs. 9, 10). In many cancers, PcG genes and proteins, especially BMI-1 and EZH2, are aberrantly overexpressed, resulting in persistent activation of stem cell programs and repression of cellular differentiation (Fig. 3; refs. 7, 11).

Figure 3.

Chromatin regulation of developmental gene expression and oncogenic dysregulation. A, Genome-wide analyses of chromatin marks indicate that in embryonic stem cells, the expression of lineage-specific transcriptional programs is suppressed, whereas pluripotency genes such as OCT4, MYC, SOX2, and BMI-1 are expressed (2–4). Key developmental genes appear to be enriched for H3K4me3 gene activation and H3K27me3 gene suppression modifications at their enhancers or promoters. These bivalent marks are thought to identify key developmental genes that are poised to be dynamically regulated upon appropriate activation of lineage-specific pathways (15). In a stem cell, these genes may be viewed as being reversibly silenced. During normal differentiation, lineage-specific programs that have been silenced in the stem cell are activated while pluripotency genes are silenced. During cell specification, nonspecified lineage gene programs are suppressed. B, oncogenic alterations may occur at any point during stem cell differentiation, leading to blocks in developmental programs. Moreover, failure to suppress alternate lineage programs could lead to tumors with mixed lineage phenotypes. In models of EFT initiation, ectopic expression of EWS-FLI1 in MSCs or NCSCs modulates the expression of numerous transcripts and proteins involved in epigenetic regulation [shown in red; the functional significance of the proteins in the box (BMI-1, EZH2, and NKX2.2) has been experimentally validated (33, 35, 37, and 39)]. Overexpression of DNMTs in these cells is also observed and contributes to preferential silencing of transcription factors that normally instruct terminal differentiation of neuromesenchymal cells (E.R. Lawlor and colleagues, unpublished data). The precise molecular mechanisms that dictate persistent PcG- and DNA-methylation–mediated repression of these developmental pathways remain to be elucidated but may involve EWS-FLI1–mediated deregulation of noncoding RNAs (miRNAs and lncRNAs).

Figure 3.

Chromatin regulation of developmental gene expression and oncogenic dysregulation. A, Genome-wide analyses of chromatin marks indicate that in embryonic stem cells, the expression of lineage-specific transcriptional programs is suppressed, whereas pluripotency genes such as OCT4, MYC, SOX2, and BMI-1 are expressed (2–4). Key developmental genes appear to be enriched for H3K4me3 gene activation and H3K27me3 gene suppression modifications at their enhancers or promoters. These bivalent marks are thought to identify key developmental genes that are poised to be dynamically regulated upon appropriate activation of lineage-specific pathways (15). In a stem cell, these genes may be viewed as being reversibly silenced. During normal differentiation, lineage-specific programs that have been silenced in the stem cell are activated while pluripotency genes are silenced. During cell specification, nonspecified lineage gene programs are suppressed. B, oncogenic alterations may occur at any point during stem cell differentiation, leading to blocks in developmental programs. Moreover, failure to suppress alternate lineage programs could lead to tumors with mixed lineage phenotypes. In models of EFT initiation, ectopic expression of EWS-FLI1 in MSCs or NCSCs modulates the expression of numerous transcripts and proteins involved in epigenetic regulation [shown in red; the functional significance of the proteins in the box (BMI-1, EZH2, and NKX2.2) has been experimentally validated (33, 35, 37, and 39)]. Overexpression of DNMTs in these cells is also observed and contributes to preferential silencing of transcription factors that normally instruct terminal differentiation of neuromesenchymal cells (E.R. Lawlor and colleagues, unpublished data). The precise molecular mechanisms that dictate persistent PcG- and DNA-methylation–mediated repression of these developmental pathways remain to be elucidated but may involve EWS-FLI1–mediated deregulation of noncoding RNAs (miRNAs and lncRNAs).

Close modal

Transcriptionally active chromatin is acetylated and methylated at H3K4 (Figs. 1 and 3; ref. 5). H3K4 methylation is supported by Trithorax group proteins with HMT activity that are encoded by mixed lineage leukemia (MLL) genes (12). Alterations in H3K4 methylation lead to differentiation defects and rearrangements of MLL1, and mutations in MLL2 and MLL3 are common in high-risk leukemias of childhood (13) and pediatric medulloblastomas (14), respectively. Of importance, in embryonic stem cells, repressed genes that are involved in early lineage commitment maintain both repressive (H3K27me3) and activating (H3K4me3) histone modifications (15). These bivalent genes are considered to be poised for rapid activation in response to appropriate differentiation signals (15), and they are frequently aberrantly irreversibly silenced in cancer (Fig. 3; ref. 16).

Nucleosome remodeling

Changes in nucleosome position along the DNA strand and conformational changes to DNA-histone interactions influence the accessibility of transcription factors to DNA. Such nucleosome remodeling is critical for normal differentiation and is controlled by ATP-dependent, multiprotein chromatin-remodeling complexes, in particular SWI/SNF (Fig. 2B; refs. 5, 17). In addition, SWI/SNF contributes to the epigenetic regulation of gene expression by competing with and antagonizing PcG protein function (18). The core subunit of SWI/SNF, SNF5 (also known as SMARCB1, INI1, and BAF47) is an established tumor suppressor that is mutated in aggressive malignant rhabdoid tumors in children (19). Mutations of other members of the SWI/SNF complex are also prominent in several aggressive adult malignancies (reviewed in ref. 17).

DNA methylation

DNA methylation at gene promoters is associated with gene silencing, and during differentiation, cellular reprogramming, or tumorigenesis, the pattern of global DNA methylation undergoes significant changes (Fig. 2C; refs. 20–22). In normal differentiated tissues, DNA methylation is quite stable and is characterized by methylated intergenic regions and unmethylated gene promoters (22). By contrast, in cancer, large regions of methylation are lost from intergenic regions and gene promoters are aberrantly hypermethylated (22). In addition, tissue-specific differentially methylated regions that are highly stable in normal tissues are highly unstable in malignant tissues, indicating epigenetic instability (22). Although DNA methylation was long considered to be irreversible, the recent discovery of TET family proteins has elucidated a physiologic mechanism of DNA demethylation (23). Through their action as 5-methylcytosine dioxygenases, TET enzymes convert 5′-methylcytosine residues on methylated DNA to 5′-hydroxymethylcytosine (Fig. 2D; ref. 24). Of importance, mutations in TET-encoding genes and genes that alter TET function are common in human myeloid malignancies (25, 26) and gliomas (27), respectively, and are associated with abnormal DNA methylation phenotypes. Hypermethylated genes in cancer are highly enriched for bivalent genes as well as other genes that are subject to PcG-mediated silencing in stem cells (16, 28). Together, these findings suggest a developmental model of cancer initiation in which tumor-initiating cells become locked in an undifferentiated state as a result of aberrant DNA methylation at PcG-marked loci (Fig. 3B).

Whether a tumor arises from an embryonic stem cell or multipotent progenitor, or from the dedifferentiation of a more specialized postnatal cell, a unifying model is that genetic alterations associated with tumorigenesis lead to initiation of malignant transformation as a result of epigenetic deregulation. Recent and emerging data generate compelling support for the critical contribution of this model to the origin and progression of pediatric solid tumors, in particular to Ewing sarcoma, neuroblastoma, and brain tumors.

Ewing sarcoma

Ewing sarcoma family tumors (EFT) are characterized by an undifferentiated histology, a highly metastatic phenotype, and the presence of chromosomal translocations that result in the creation of fusion oncogenes (29). In 85% of cases, the resulting chimeric protein is a fusion between EWS and FLI1 (30). EWS-FLI1 functions as an aberrant transcription factor and is believed to be an initiating tumorigenic event. The very primitive neuroectodermal histology of EFTs and their diverse presentation in bones and soft tissues suggest an early stem or progenitor cell of origin. Indeed, recent experimental evidence supports this hypothesis, and bone progenitors, mesenchymal stem cells (MSC), and neural crest stem cells (NCSC) have all been implicated as potential cells of origin (31–35).

Initial investigations into the function of EWS-FLI1 focused largely on identifying genes that were induced by the fusion. In the course of those studies, several promising candidates were identified, and genes such as NKX2.2 (36), NR0B1 [DAX1 (37)], and EZH2 (38) are now well established as direct transcriptional targets of EWS-FLI1. However, EWS-FLI1 represses as many genes as it induces (34, 39, 40), and the mechanisms by which EWS-FLI1 represses transcription and the contribution of gene repression to the EFT phenotype have become the focus of intense investigation.

A significant portion of EWS-FLI1–repressed targets are downregulated by the activity of its target gene, NKX2.2, which functions to repress transcription by recruiting TLE transcriptional corepressors and HDACs to target gene promoters (39). Similarly, EWS-FLI1–mediated induction of EZH2 blocks differentiation of MSC and leads to the repression of genes involved in neuroectodermal and endothelial differentiation (38, 41). In NCSC, EZH2 and BMI-1 are both induced by EWS-FLI1; however, unlike EZH2, the mechanism of BMI-1 induction is likely to be indirect (34). This upregulation of BMI-1 leads to repression of p16 and maintenance of stemness, supporting the hypothesis that epigenetic silencing of p16 may be a key step in EFT initiation (Fig. 3B; ref. 34). Sustained expression of EWS-FLI1 in NCSCs results in progressive downregulation of transcription factors that are normally required for neuroectodermal and skeletal differentiation (ref. 34; C. von Levetzow and E.R. Lawlor, unpublished data). In established EFT, tumorigenicity is dependent on continued overexpression of EZH2 and BMI-1 (32, 38, 42, 43). To exploit this property, Thiel and colleagues (44) recently proposed cell therapy with cytotoxic T cells directed against EZH2 as a novel approach to EFT therapy, showing that the abnormal cancer epigenome could be a source of novel antigenic targets for immunotherapy (45).

Finally, regulation of PcG protein expression and function is mediated by a complex network of microRNAs [miRNA (46)] and by long noncoding RNAs [lncRNAs (7)]. EWS-FLI1 modulates the expression of both miRNAs (47) and lncRNAs (48), so it will be interesting to discover whether EWS-FLI1–mediated deregulation of ncRNA transcripts contributes to PcG protein dysfunction. In addition, the contribution of altered DNA promoter methylation to EFT pathogenesis is beginning to come into focus. A global analysis of DNA promoter methylation has revealed that the CpG islands of PcG target genes are aberrantly hypermethylated in EFT, and the promoters of transcription factors that are involved in neural differentiation become progressively methylated over time in EWS-FLI1–expressing NCSCs (C. von Levetzow and E.R. Lawlor, unpublished data). Thus, EWS-FLI1 drives EFT pathogenesis by invoking global deregulation of the epigenome through diverse mechanisms (Fig. 3B).

Progression of established EFT depends on continued expression of EWS-FLI1 (36). Inhibition of tumor growth following EWS-FLI1 inhibition is associated with reexpression of numerous repressed target genes, suggesting that the oncogenic phenotype is dependent, at least in part, on maintaining epigenetic repression (36). In support of this notion, targeted knockdown of BMI-1 in EFT leads to reduced tumorigenicity and induction of differentiation genes (Fig. 4A; ref. 42). In addition, exposure of EFT cells to HDAC inhibitors (Table 1) restores the expression of numerous EWS-FLI1-repressed genes and also inhibits growth and tumorigenicity (39, 49). Combining HDAC inhibition with decitabine, an inhibitor of DNA methylation, potentiates the growth-inhibitory effects of either agent alone, supporting a role for combination approaches to epigenetic therapy (50). Direct pharmacologic targeting of transcription factors continues to be an immense therapeutic challenge. In EFT, targeting the epigenome may be an effective way to circumvent the oncogenic activity of EWS-FLI1 without having to target the oncogene itself directly.

Figure 4.

Inhibition of PcG proteins promotes tumor cell differentiation. A, BMI-1 knockdown (shBMI1) EFT cells have reduced tumorigenic capacity in immune-deficient mice (42). As shown here, TC-71 xenografts established from stably transduced BMI-1 knockdown cells express higher levels of peripherin, a cytoskeletal marker of differentiated peripheral neurons, than do tumors established from nonsilenced control cells (shNS). Top, quantitative reverse transcriptase PCR (Q-RT-PCR). Expression of PRPH is normalized relative to expression of GAPDH (Taqman assay; Applied Biosystems). Bottom, peripherin immunostaining of fresh-frozen sections (peripherin antibody 1:100 dilution; catalog number AB1530; Millipore). B, DZnep inhibits EZH2 as well as histone methylation more broadly and induces apoptosis or differentiation in preclinical models of a number of tumors (102, 103). Treatment of the neuroblastoma cell line SKN-BE2 for 4 days with DZnep inhibits growth and induces morphologic differentiation.

Figure 4.

Inhibition of PcG proteins promotes tumor cell differentiation. A, BMI-1 knockdown (shBMI1) EFT cells have reduced tumorigenic capacity in immune-deficient mice (42). As shown here, TC-71 xenografts established from stably transduced BMI-1 knockdown cells express higher levels of peripherin, a cytoskeletal marker of differentiated peripheral neurons, than do tumors established from nonsilenced control cells (shNS). Top, quantitative reverse transcriptase PCR (Q-RT-PCR). Expression of PRPH is normalized relative to expression of GAPDH (Taqman assay; Applied Biosystems). Bottom, peripherin immunostaining of fresh-frozen sections (peripherin antibody 1:100 dilution; catalog number AB1530; Millipore). B, DZnep inhibits EZH2 as well as histone methylation more broadly and induces apoptosis or differentiation in preclinical models of a number of tumors (102, 103). Treatment of the neuroblastoma cell line SKN-BE2 for 4 days with DZnep inhibits growth and induces morphologic differentiation.

Close modal
Table 1.

Epigenetic modifiers—current drugs and agents in development

Class of agentTargetStatusTumorReferences
HDAC inhibitorsa 
Vorinostat [SAHA, Zolinza (Merck)] HDAC1–3,6 FDAb Cutaneous T-cell lymphoma (86, 95, 96) 
  Ped. phase I Relapsed solid tumors  
Romidepsin [FK228, Istodax (Celgene)] HDAC1–3,8 FDAb Cutaneous, peripheral T-cell lymphoma (86) 
 weak HDAC6,4 Ped. phase I Relapsed solid tumors (97) 
Entinostat (SNDX-275), panobinostat (LBH589), belinostat (PDX101) HDAC1 Phase II Breast (86) 
 HDAC1–4 Phase I Lymphoma  
 HDAC1–4 weak HDAC8 Phase I Relapsed solid tumors  
Valproic acidc HDAC1–3, weak HDAC8 Ped. phase I, Refractory solid or CNS tumors (86, 98) 
PCI-34051 HDAC8 Preclinical  (99) 
Modifiers of acetylated histones 
JQ1 KAC Preclinical Lymphoma, MYC-driven tumors (75, 100) 
HMT inhibitors 
EZH2 (SET domain) inhibitors (Epizyme, Inc.) EZH2 Preclinical EZH2 mutated lymphomas (101) 
DZNep EZH2 Preclinical  (102, 103) 
EPZ004777 DOT1L Preclinical MLL-rearranged AML and ALL (104) 
Histone demethylase inhibitors 
Monamine oxidase inhibitors: LSD1 Preclinical  (61) 
Pargyline, clorgyline, tranylcyprominec  FDAc   
Polyamine analoguesc LSD1 Preclinical  (105) 
Bisguanidines, biguanides     
DNA methylation inhibitors 
Decitabine [Dacogen (Eisai)] DNMT FDAb MDS, CML (86) 
Azacytidine [Vidaza (Celgene)]     
Zebularine DNMT Clinical trials MDS, CML (86) 
Class of agentTargetStatusTumorReferences
HDAC inhibitorsa 
Vorinostat [SAHA, Zolinza (Merck)] HDAC1–3,6 FDAb Cutaneous T-cell lymphoma (86, 95, 96) 
  Ped. phase I Relapsed solid tumors  
Romidepsin [FK228, Istodax (Celgene)] HDAC1–3,8 FDAb Cutaneous, peripheral T-cell lymphoma (86) 
 weak HDAC6,4 Ped. phase I Relapsed solid tumors (97) 
Entinostat (SNDX-275), panobinostat (LBH589), belinostat (PDX101) HDAC1 Phase II Breast (86) 
 HDAC1–4 Phase I Lymphoma  
 HDAC1–4 weak HDAC8 Phase I Relapsed solid tumors  
Valproic acidc HDAC1–3, weak HDAC8 Ped. phase I, Refractory solid or CNS tumors (86, 98) 
PCI-34051 HDAC8 Preclinical  (99) 
Modifiers of acetylated histones 
JQ1 KAC Preclinical Lymphoma, MYC-driven tumors (75, 100) 
HMT inhibitors 
EZH2 (SET domain) inhibitors (Epizyme, Inc.) EZH2 Preclinical EZH2 mutated lymphomas (101) 
DZNep EZH2 Preclinical  (102, 103) 
EPZ004777 DOT1L Preclinical MLL-rearranged AML and ALL (104) 
Histone demethylase inhibitors 
Monamine oxidase inhibitors: LSD1 Preclinical  (61) 
Pargyline, clorgyline, tranylcyprominec  FDAc   
Polyamine analoguesc LSD1 Preclinical  (105) 
Bisguanidines, biguanides     
DNA methylation inhibitors 
Decitabine [Dacogen (Eisai)] DNMT FDAb MDS, CML (86) 
Azacytidine [Vidaza (Celgene)]     
Zebularine DNMT Clinical trials MDS, CML (86) 

aTarget specificity for particular HDACs based on functional data (95).

bFDA-approved for a cancer therapy indication.

cFDA-approved for noncancer indications.

Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; CML, chronic myelogenous leukemia; CNS, central nervous system; DZNep, 3-deazaneplanocin A; FDA, U.S. Food and Drug Administration; MDS, myelodysplastic syndrome; Ped., pediatric.

Neuroblastoma

Neuroblastomas are neural-crest–derived tumors that express genes characteristic of sympathoadrenal cell lineages. Mutations in PHOX2B, a major regulator of sympathoadrenal development, have been identified in 6% of familial neuroblastomas and also, more rarely, in neuroblastoma cell lines (51). In the 1980s, histologic classification of neuroblastomas into subsets based on the extent of differentiation was prognostically relevant (52). Functional studies contributed to the concept that neuroblastoma cells correspond to different stages of sympathoadrenal development and retain the potential to differentiate into a number of neural crest cell lineages, and thus represent a multipotent sympathoadrenal progenitor cell with distinct tumorigenic potential (53, 54). Consistent with these concepts, aggressive neuroblastoma tumors are characterized by increased expression of cell-cycle genes (55), whereas ganglioneuroma and ganglioneuroblastoma express genes associated with neural development (56).

EZH2 is elevated in poor-prognosis, undifferentiated neuroblastoma and is associated with enrichment of H3K27me3 at the promoters of tumor suppressor genes such as CASZ1, RUNX3, NGFR (p75), and NTRK1 [TrkA (57)]. The cause of such elevated EZH2 levels is still unknown, but a number of genetic alterations at the EZH2 locus may contribute: 7q35-36 is amplified in 10% to 15% of tumors, and >50% of neuroblastoma tumors have gains of the entire Chr7 or 7q (58). BMI-1 is a direct transcriptional target of MYCN (59); it is also overexpressed by neuroblastomas and is essential for their tumorigenicity (60). In addition, the lysine-specific demethylase LSD1 is overexpressed in poorly differentiated neuroblastoma (61). In embryonic stem cells, LSD1 preferentially demethylates H3K4me3, thus favoring PcG-associated H3K27me3 silencing at bivalent loci and maintenance of stemness. This physiologic function of LSD1 and EZH2 overexpression most likely contributes to the poor prognosis that is associated with LSD1-overexpressing neuroblastoma compared with more-differentiated forms of the tumor (61).

The relationship between PcG protein dysregulation and DNA methylation in neuroblastoma tumors is tenuous but intriguing. The CHD5 tumor suppressor gene, which is part of a family of chromatin remodeling proteins, is in a chromosomal region that is subject to loss of heterozygosity in a number of tumors, including neuroblastoma (62). CHD5 contains a bivalent chromatin mark in stem cells (15), and in neuroblastoma cells with loss of heterozygosity, the remaining allele is silenced via DNA methylation (63). An examination of genome-wide expression microarray data from primary neuroblastoma tumors (R2 database, http://hgserver1.amc.nl/cgi-bin/r2/main.cgi) reveals an inverse correlation between EZH2 and CHD5 expression (r = −0.314, P = 2.6 × 10−3) and a direct correlation between EZH2 and DNMT1 (r = 0.679, P = 3.5 × 10−13). Thus, overexpression of PcG proteins in neuroblastoma may promote recruitment of DNMTs and induce permanent gene silencing of key developmental loci. It is not clear whether silencing of a single gene or an entire pathway is needed for neuroblastoma initiation or progression, but a number of genes, including a commonly hypermethylated gene in cancer (HIC1), putative tumor suppressor genes (RASSF1A and PRKCDBP), differentiation genes (HOXA9), and apoptosis genes (CASP8, APAF1, and TMS1), have been consistently identified (62, 64–67). In addition, emerging data from unbiased, global approaches have confirmed established loci and identified novel DNA methylated regions (telomeric silencing of 1p, 3p, 11q, and 19p) and a methylator phenotype that is associated with a worse clinical outcome (65, 67, 68).

In addition to MYCN's association with activating histone chromatin modifications (69), there is also an intriguing association of MYCN amplification with DNA methylation. This was first noted with CASP8 (70) and has now been associated with additional loci (66, 67). In neuroblastoma cell lines, genome-wide MYCN DNA binding is significantly associated with the binding of MeCP2, a CpG methyl-binding protein (71). At gene promoters, transcription is relatively high when MYCN is bound alone, intermediate when both MYCN and MeCP2 are present, and low when only MeCP2 is present. This suggests that MYCN may serve as an initial but transient focus to recruit components required to mediate DNA methylation (71).

There is abundant evidence to support the use of epigenetic modifiers in neuroblastoma therapy. First, the ability of retinoids to restore differentiation indicates that despite the genetic alterations associated with high-risk tumors, the regulatory signaling pathways that control growth and differentiation are intact but dysregulated. Indeed, it is becoming increasingly evident that retinoids function to relieve epigenetic suppression. First, neuroblastoma cells treated with retinoids show decreases in steady-state levels of BMI-1 (60), EZH2 (D.Y. Oh and C.J. Thiele, unpublished data), and LSD1 (61), and a recent genome-wide study indicated that retinoids reverse the methylation status of hundreds of gene promoters (72). Second, HDAC inhibitors, either alone or in combination with cis-retinoic acid, inhibit neuroblastoma growth in vitro and in vivo (73, 74). Third, reactivation of caspase 8 in drug-resistant neuroblastoma cells by exposure to DNA methylation inhibitors restores sensitivity to standard cytotoxic agents (70). Fourth, inhibition of EZH2 by 3-deazaneplanocin A (DZNep) leads to reexpression of EZH2 silenced tumor suppressor genes and results in decreased growth and differentiation of neuroblastoma cells (Fig. 4B, ref. 57). Finally, the most aggressive neuroblastomas are driven by aberrant activation of MYCN. Recent studies showed that JQ1, a novel small-molecule inhibitor of the chromatin-modifying cofactor BRD4, dramatically inhibits proliferation and promotes terminal differentiation of acute myelogenous leukemia (AML) cells, in part by suppressing MYC function (75). Whether epigenetic therapy with JQ1 can be used to block the oncogenic activity of MYCN in neuroblastoma remains to be determined, but these findings provide an exciting new opportunity for investigation.

Brain tumors

Epigenetic deregulation is emerging as a fundamental process underlying the pathogenesis of pediatric brain tumors. Hypermethylation of the RASSF1A tumor suppressor gene has been identified in nearly 90% of medulloblastomas and ependymomas (76), and upregulation of PcG proteins, in particular BMI-1 and EZH2, is common and is associated with worse clinical outcomes (77, 78). Intriguingly, recent next-generation sequencing studies of pediatric medulloblastomas revealed that although tremendous genetic diversity exists between individual tumors, there is a marked overrepresentation of disruptions in genes that encode for chromatin modifiers and epigenetic regulators (14, 79). In a study by Northcott and colleagues (79), deletions in individual genes that encode H3K9 methyltransferases (i.e., EHMT1 and SMYD4) were detected in 2% of cases in a series of 212 tumors, and H3K9 demethylase genes were selectively amplified in another 2%. In total, mutations, deletions, or amplifications in genes that converge on modulating H3K9 methylation were detected in 19% of the tumors examined in that study, and an absence of nuclear staining for methylated H3K9 was confirmed in 41% of cases in an independent cohort (79). Dimethylation of H3K9 is required for silencing of proliferative genes and successful terminal differentiation of progenitor cells in the external granule layer (79). Mutations that disrupt H3K9 methylation likely contribute to malignant transformation by blocking normal differentiation (79). In a second study, inactivating mutations of the HMTs MLL2 and MLL3 were detected in 16% of primary tumors, and mutations in the SWI/SNF components SMARCA4 and ARID1A were detected in another 4% (14). Thus, mutations in epigenetic regulators figure prominently in pediatric medulloblastoma, and cumulatively these lesions contribute to tumor initiation and progression by repressing normal developmental pathways while promoting the maintenance of a more stem-like state.

Next-generation sequencing studies of gliomas have also uncovered a basis for epigenetic deregulation, with the discovery that 70% to 80% of grade II and III astrocytomas harbor a mutation in either the IDH1 or IDH2 isocitrate dehydrogenase gene (80). IDHs produce α-ketoglutarate, a necessary cosubstrate for histone demethylases and TET family proteins (25). Mutated IDH proteins produce D-2-hydroxyglutarate, which acts as a competitive inhibitor of α-ketoglutarate and thereby inhibits histone and DNA demethylation (81). Thus, IDH-mutated gliomas are epigenomically abnormal and this contributes to an abnormal DNA methylator phenotype (82). Of importance, however, mutations in IDH genes are associated with younger age and an improved prognosis, indicating that epigenetically driven tumors may be less aggressive and more responsive to therapy than tumors that are characterized by genetic instability, such as those that occur in older patients (25).

Other embryonic solid tumors

Genome-wide studies of Wilms tumor chromatin and DNA methylation have been extremely informative and have identified global epigenetic aberrations beyond the well-established hypermethylation of H19 that contributes to loss of imprinting and overexpression of IGF2 (83). In particular, the chromatin landscape of Wilms tumors was shown to be highly related to embryonic stem cells and associated with upregulation of PcG activity, abnormal retention of bivalent marks, and silencing of genes that direct early renal differentiation (84). Although the precise cell of origin of retinoblastoma tumors remains controversial, the clinical presentation of these tumors before birth and in early infancy leaves no doubt as to their embryonic origin. Of interest, a recent study found that developmental pathways that are normally expressed in a mutually exclusive fashion during normal retinal cell development are abnormally coexpressed in single retinoblastoma cells (85). Although the mechanisms underlying this observation remain to be elucidated, it is highly probable that disruption of normal epigenetic regulation within developing retinal cells contributes to this oncogenic developmental abnormality.

Therapeutic opportunities and challenges

U.S. Food and Drug Administration (FDA)-approved use of epigenetic modifiers is currently limited to 2 classes of agents (Table 1). Specifically, HDAC inhibitors (vorinostat and romidepsin) and DNA methylation inhibitors [5-azacytidine and deoxyazacytidine (decitabine)] are approved for use in the treatment of cutaneous T-cell lymphomas and myelodysplastic syndrome, respectively, and function to reactivate aberrantly silenced genes (86). These agents, as well as other classes of HDAC inhibitors (e.g., valproate), are now being evaluated in early-phase clinical trials in adult solid tumors, in particular for patients with relapsed and metastatic sarcomas (http://www.cancer.gov/clinicaltrials). Pediatric phase I studies for romidepsin, vorinostat, and valproic acid have been completed, and investigators report that each agent is well tolerated and results in increased acetylated-H3 histones in peripheral blood lymphocytes, a surrogate marker of drug target activity (Table 1). No objective responses were seen with the single agents, but a complete response in one neuroblastoma patient who received a combination of 13-cis retinoic acid and vorinostat in the phase I study encouraged the testing of combination treatments. Currently the New Approaches to Neuroblastoma Therapy consortium is evaluating the toxicity of vorinostat in combination with 13-cis-retinoic acid (http://www.cancer.gov/clinicaltrials; NCT01208454) or meta-iodo-benzyl-guanidine (131I-MIBG) therapy [NCT01019850 (87)]. A phase I/II study is also under way evaluating vorinostat in combination with etoposide in pediatric patients with relapsed and refractory sarcomas as well as other solid tumors (NCT01294670). Unfortunately, a recent Children's Oncology Group study found that dose-limiting hematologic toxicities were experienced by children with relapsed solid tumors who were treated with low-dose decitabine in combination with cytotoxic chemotherapy (88). It remains to be determined whether drug toxicity and response rates to HDAC and DNA methylation inhibitors are strictly determined by the somatic tumor genotype or whether heritable germline factors may also contribute to outcome (89). Thus, there is still much work to be done to determine the optimal dose and schedule regimens of currently available drugs, especially with regard to heavily pretreated patients. Strong consideration should be given to testing epigenetic modifiers as components of initial therapy in newly diagnosed patients with high-risk disease.

Current HDAC and DNA methylation inhibitors are very nonspecific in their action, invoking genome-wide effects and inducing cell death and differentiation through multiple different molecular mechanisms (90). Approved HDAC inhibitors broadly inhibit the activity of multiple different HDACs (Table 1), and it is hoped that as new, more target-specific agents are developed, there will be fewer dose-limiting toxicities. An improved understanding of the biology of epigenetic regulation has also contributed to the development of new classes of agents that have been designed to specifically target the cancer epigenome (Table 1). In addition, as discussed above with respect to retinoids in neuroblastoma, an improved understanding of developmental biology is uncovering epigenetic mechanisms of action for established drugs. This raises the possibility that in the future, other drugs may also be identified for repurposing as epigenetic modifiers.

Early failures with HDAC and DNA methylation inhibitors in clinical studies of adult solid tumors dampened initial enthusiasm for their potential as effective therapeutic agents. However, an improved understanding of the mechanisms of drug action and of tumor biology led to changes to drug dose and delivery schedules that have proved beneficial (86). It is now apparent that epigenetic modifiers exert their biologic effects at doses far below the maximum tolerated doses that are identified in classic phase I trials. In addition, single-agent therapy with DNMT inhibitors may lead to only transient reexpression of silenced genes as a result of continued histone deacetylation of the repressed loci (91). Therefore, chronic low doses of epigenetic modifiers (i.e., DNMT inhibitors together with HDAC inhibitors) in combination with standard cytotoxic therapy may be required to normalize the epigenetic landscape of tumor cells and induce sustainable clinical remissions (86, 91). Indeed, in a recent clinical trial, low-dose combination epigenetic therapy successfully induced clinical responses in heavily pretreated patients with non–small cell lung cancer (92). However, it is noteworthy that the responses occurred gradually over several months. This observation is consistent with studies of epigenetic modifiers in animal models, which showed that one can better determine the therapeutic efficacy of these agents by evaluating tumor-initiating potential rather than tumor shrinkage (93). Thus, standard Response Evaluation Criteria in Solid Tumors (RECIST) may not be the best initial tool to evaluate epigenetic drug efficacy. Ideally, biomarkers of drug efficacy should be used to ascertain that the agents are having the predicted biologic effect. Furthermore, it will be imperative to ensure the availability of tissues for pathologic assessment of response whenever new epigenetically targeted agents are introduced into the clinical setting.

Genetic mutations that result in alterations in DNA sequence have classically been considered drivers of tumorigenicity. The recent explosion of knowledge about stem cell and developmental biology combined with the advent of next-generation sequencing technologies has led to the realization that disruptions to the epigenome are at least equal contributors to the pathogenesis of human cancer (86). Thus, one might consider that tolerance and propagation of genetic lesions that initiate malignant transformation are dependent on epigenetic plasticity in the target cell (94). Nowhere is this model more supported than in the diverse array of pediatric solid tumors that, in contrast to adult malignancies, arise as a consequence of relatively few genetic mutations and progress to invasive, drug-resistant, and metastatic phenotypes despite the persistence of relatively stable genomes (14, 94). Although epigenetic therapies have not yet been extensively tested in children, the essential contribution of epigenetic deregulation to pediatric solid tumors provides a compelling rationale for their use. Continued elucidation of the contribution of epigenetic deregulation to the pathogenesis of these tumors will provide critical insights into the role of epigenomic instability as a driving force behind the malignant phenotype, and will facilitate the translation of this knowledge into effective epigenetically targeted therapies.

No potential conflicts of interest were disclosed.

Conception and design: E.R. Lawlor, C. J. Thiele

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): E.R. Lawlor

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): E.R. Lawlor, C. J. Thiele

Writing, review, and/or revision of the manuscript: E.R. Lawlor, C. J. Thiele

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): E.R. Lawlor

Study supervision: C. J. Thiele

The authors acknowledge members of their respective laboratories for helpful discussions and data generation. We apologize to our respected colleagues whose work we were unable to cite due to space constraints.

E.R. Lawlor was supported by a Stand Up To Cancer Innovative Research Grant, a program of the Entertainment Industry Foundation (AACR-SU2C-IRB-1309); the Russell G. Adderley Endowment, Department of Pediatrics, University of Michigan; and the National Institutes of Health (R01-CA134604). C.J. Thiele was supported by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health.

1.
Maris
JM
,
Denny
CT
. 
Focus on embryonal malignancies
.
Cancer Cell
2002
;
2
:
447
50
.
2.
Lee
TI
,
Jenner
RG
,
Boyer
LA
,
Guenther
MG
,
Levine
SS
,
Kumar
RM
, et al
Control of developmental regulators by Polycomb in human embryonic stem cells
.
Cell
2006
;
125
:
301
13
.
3.
Mikkelsen
TS
,
Ku
M
,
Jaffe
DB
,
Issac
B
,
Lieberman
E
,
Giannoukos
G
, et al
Genome-wide maps of chromatin state in pluripotent and lineage-committed cells
.
Nature
2007
;
448
:
553
60
.
4.
Meissner
A
,
Mikkelsen
TS
,
Gu
H
,
Wernig
M
,
Hanna
J
,
Sivachenko
A
, et al
Genome-scale DNA methylation maps of pluripotent and differentiated cells
.
Nature
2008
;
454
:
766
70
.
5.
Li
B
,
Carey
M
,
Workman
JL
. 
The role of chromatin during transcription
.
Cell
2007
;
128
:
707
19
.
6.
Bannister
AJ
,
Kouzarides
T
. 
Regulation of chromatin by histone modifications
.
Cell Res
2011
;
21
:
381
95
.
7.
Bracken
AP
,
Helin
K
. 
Polycomb group proteins: navigators of lineage pathways led astray in cancer
.
Nat Rev Cancer
2009
;
9
:
773
84
.
8.
Pietersen
AM
,
van Lohuizen
M
. 
Stem cell regulation by polycomb repressors: postponing commitment
.
Curr Opin Cell Biol
2008
;
20
:
201
7
.
9.
Viré
E
,
Brenner
C
,
Deplus
R
,
Blanchon
L
,
Fraga
M
,
Didelot
C
, et al
The Polycomb group protein EZH2 directly controls DNA methylation
.
Nature
2006
;
439
:
871
4
.
10.
Negishi
M
,
Saraya
A
,
Miyagi
S
,
Nagao
K
,
Inagaki
Y
,
Nishikawa
M
, et al
Bmi1 cooperates with Dnmt1-associated protein 1 in gene silencing
.
Biochem Biophys Res Commun
2007
;
353
:
992
8
.
11.
Berdasco
M
,
Esteller
M
. 
Aberrant epigenetic landscape in cancer: how cellular identity goes awry
.
Dev Cell
2010
;
19
:
698
711
.
12.
Cosgrove
MS
,
Patel
A
. 
Mixed lineage leukemia: a structure-function perspective of the MLL1 protein
.
FEBS J
2010
;
277
:
1832
42
.
13.
Loh
ML
,
Mullighan
CG
. 
Advances in the genetics of high-risk childhood B-progenitor acute lymphoblastic leukemia and juvenile myelomonocytic leukemia: implications for therapy
.
Clin Cancer Res
2012
;
18
:
2754
67
.
14.
Parsons
DW
,
Li
M
,
Zhang
X
,
Jones
S
,
Leary
RJ
,
Lin
JC
, et al
The genetic landscape of the childhood cancer medulloblastoma
.
Science
2011
;
331
:
435
9
.
15.
Bernstein
BE
,
Mikkelsen
TS
,
Xie
X
,
Kamal
M
,
Huebert
DJ
,
Cuff
J
, et al
A bivalent chromatin structure marks key developmental genes in embryonic stem cells
.
Cell
2006
;
125
:
315
26
.
16.
Ohm
JE
,
Baylin
SB
. 
Stem cell chromatin patterns: an instructive mechanism for DNA hypermethylation?
Cell Cycle
2007
;
6
:
1040
3
.
17.
Wilson
BG
,
Roberts
CW
. 
SWI/SNF nucleosome remodellers and cancer
.
Nat Rev Cancer
2011
;
11
:
481
92
.
18.
Wilson
BG
,
Wang
X
,
Shen
X
,
McKenna
ES
,
Lemieux
ME
,
Cho
YJ
, et al
Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation
.
Cancer Cell
2010
;
18
:
316
28
.
19.
Versteege
I
,
Sévenet
N
,
Lange
J
,
Rousseau-Merck
MF
,
Ambros
P
,
Handgretinger
R
, et al
Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer
.
Nature
1998
;
394
:
203
6
.
20.
Doi
A
,
Park
IH
,
Wen
B
,
Murakami
P
,
Aryee
MJ
,
Irizarry
R
, et al
Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts
.
Nat Genet
2009
;
41
:
1350
3
.
21.
Irizarry
RA
,
Ladd-Acosta
C
,
Wen
B
,
Wu
Z
,
Montano
C
,
Onyango
P
, et al
The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores
.
Nat Genet
2009
;
41
:
178
86
.
22.
Hansen
KD
,
Timp
W
,
Bravo
HC
,
Sabunciyan
S
,
Langmead
B
,
McDonald
OG
, et al
Increased methylation variation in epigenetic domains across cancer types
.
Nat Genet
2011
;
43
:
768
75
.
23.
Bhutani
N
,
Burns
DM
,
Blau
HM
. 
DNA demethylation dynamics
.
Cell
2011
;
146
:
866
72
.
24.
Ito
S
,
Shen
L
,
Dai
Q
,
Wu
SC
,
Collins
LB
,
Swenberg
JA
, et al
Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine
.
Science
2011
;
333
:
1300
3
.
25.
Gupta
R
,
Webb-Myers
R
,
Flanagan
S
,
Buckland
ME
. 
Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications
.
J Clin Pathol
2011
;
64
:
835
44
.
26.
Figueroa
ME
,
Abdel-Wahab
O
,
Lu
C
,
Ward
PS
,
Patel
J
,
Shih
A
, et al
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation
.
Cancer Cell
2010
;
18
:
553
67
.
27.
Abdel-Wahab
O
,
Mullally
A
,
Hedvat
C
,
Garcia-Manero
G
,
Patel
J
,
Wadleigh
M
, et al
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
.
Blood
2009
;
114
:
144
7
.
28.
Widschwendter
M
,
Fiegl
H
,
Egle
D
,
Mueller-Holzner
E
,
Spizzo
G
,
Marth
C
, et al
Epigenetic stem cell signature in cancer
.
Nat Genet
2007
;
39
:
157
8
.
29.
Balamuth
NJ
,
Womer
RB
. 
Ewing's sarcoma
.
Lancet Oncol
2010
;
11
:
184
92
.
30.
Kovar
H
. 
Downstream EWS/FLI1—upstream Ewing's sarcoma
.
Genome Med
2010
;
2
:
8
.
31.
Riggi
N
,
Cironi
L
,
Provero
P
,
Suvà
ML
,
Kaloulis
K
,
Garcia-Echeverria
C
, et al
Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells
.
Cancer Res
2005
;
65
:
11459
68
.
32.
Riggi
N
,
Suvà
ML
,
Suvà
D
,
Cironi
L
,
Provero
P
,
Tercier
S
, et al
EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells
.
Cancer Res
2008
;
68
:
2176
85
.
33.
Riggi
N
,
Suvà
ML
,
De Vito
C
,
Provero
P
,
Stehle
JC
,
Baumer
K
, et al
EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells
.
Genes Dev
2010
;
24
:
916
32
.
34.
von
Levetzow
C
,
Jiang
X
,
Gwye
Y
,
von Levetzow
G
,
Hung
L
,
Cooper
A
, et al
Modeling initiation of Ewing sarcoma in human neural crest cells
.
PLoS ONE
2011
;
6
:
e19305
.
35.
Castillero-Trejo
Y
,
Eliazer
S
,
Xiang
L
,
Richardson
JA
,
Ilaria
RL
 Jr
. 
Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells. Results in EWS/FLI-1-dependent, Ewing sarcoma-like tumors
.
Cancer Res
2005
;
65
:
8698
705
.
36.
Smith
R
,
Owen
LA
,
Trem
DJ
,
Wong
JS
,
Whangbo
JS
,
Golub
TR
, et al
Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma
.
Cancer Cell
2006
;
9
:
405
16
.
37.
Kinsey
M
,
Smith
R
,
Lessnick
SL
. 
NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma
.
Mol Cancer Res
2006
;
4
:
851
9
.
38.
Richter
GH
,
Plehm
S
,
Fasan
A
,
Rössler
S
,
Unland
R
,
Bennani-Baiti
IM
, et al
EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation
.
Proc Natl Acad Sci U S A
2009
;
106
:
5324
9
.
39.
Owen
LA
,
Kowalewski
AA
,
Lessnick
SL
. 
EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma
.
PLoS ONE
2008
;
3
:
e1965
.
40.
Kauer
M
,
Ban
J
,
Kofler
R
,
Walker
B
,
Davis
S
,
Meltzer
P
, et al
A molecular function map of Ewing's sarcoma
.
PLoS ONE
2009
;
4
:
e5415
.
41.
Burdach
S
,
Plehm
S
,
Unland
R
,
Dirksen
U
,
Borkhardt
A
,
Staege
MS
, et al
Epigenetic maintenance of stemness and malignancy in peripheral neuroectodermal tumors by EZH2
.
Cell Cycle
2009
;
8
:
1991
6
.
42.
Douglas
D
,
Hsu
JH
,
Hung
L
,
Cooper
A
,
Abdueva
D
,
van Doorninck
J
, et al
BMI-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression
.
Cancer Res
2008
;
68
:
6507
15
.
43.
Hsu
JH
,
Lawlor
ER
. 
BMI-1 suppresses contact inhibition and stabilizes YAP in Ewing sarcoma
.
Oncogene
2011
;
30
:
2077
85
.
44.
Thiel
U
,
Pirson
S
,
Müller-Spahn
C
,
Conrad
H
,
Busch
DH
,
Bernhard
H
, et al
Specific recognition and inhibition of Ewing tumour growth by antigen-specific allo-restricted cytotoxic T cells
.
Br J Cancer
2011
;
104
:
948
56
.
45.
Lee
DW
,
Barrett
DM
,
Mackall
C
,
Orentas
R
,
Grupp
SA
. 
The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer
.
Clin Cancer Res
2012
;
18
:
2780
90
.
46.
Cao
Q
,
Mani
RS
,
Ateeq
B
,
Dhanasekaran
SM
,
Asangani
IA
,
Prensner
JR
, et al
Coordinated regulation of polycomb group complexes through microRNAs in cancer
.
Cancer Cell
2011
;
20
:
187
99
.
47.
Ban
J
,
Jug
G
,
Mestdagh
P
,
Schwentner
R
,
Kauer
M
,
Aryee
DN
, et al
Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma
.
Oncogene
2011
;
30
:
2173
80
.
48.
Bajaj
SV
,
Wai
DH
,
Buckley
JD
,
Kapranov
P
,
Lawlor
ER
,
Triche
TJ
. 
A large non-coding RNA that is characteristic of Ewing sarcoma family of tumors [abstract]
.
In:
Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research
;
2011 Apr 2–6; Orlando, FL. Philadelphia (PA): AACR
; 
2011
.
Abstract nr 1182
.
49.
Jaboin
J
,
Wild
J
,
Hamidi
H
,
Khanna
C
,
Kim
CJ
,
Robey
R
, et al
MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors
.
Cancer Res
2002
;
62
:
6108
15
.
50.
Hurtubise
A
,
Bernstein
ML
,
Momparler
RL
. 
Preclinical evaluation of the antineoplastic action of 5-aza-2¢-deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells
.
Cancer Cell Int
2008
;
8
:
16
.
51.
Raabe
EH
,
Laudenslager
M
,
Winter
C
,
Wasserman
N
,
Cole
K
,
LaQuaglia
M
, et al
Prevalence and functional consequence of PHOX2B mutations in neuroblastoma
.
Oncogene
2008
;
27
:
469
76
.
52.
Shimada
H
,
Chatten
J
,
Newton
WA
 Jr
,
Sachs
N
,
Hamoudi
AB
,
Chiba
T
, et al
Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas
.
J Natl Cancer Inst
1984
;
73
:
405
16
.
53.
Cooper
MJ
,
Hutchins
GM
,
Cohen
PS
,
Helman
LJ
,
Mennie
RJ
,
Israel
MA
. 
Human neuroblastoma tumor cell lines correspond to the arrested differentiation of chromaffin adrenal medullary neuroblasts
.
Cell Growth Differ
1990
;
1
:
149
59
.
54.
Gaetano
C
,
Matsumoto
K
,
Thiele
CJ
. 
In vitro activation of distinct molecular and cellular phenotypes after induction of differentiation in a human neuroblastoma cell line
.
Cancer Res
1992
;
52
:
4402
7
.
55.
Krasnoselsky
AL
,
Whiteford
CC
,
Wei
JS
,
Bilke
S
,
Westermann
F
,
Chen
QR
, et al
Altered expression of cell cycle genes distinguishes aggressive neuroblastoma
.
Oncogene
2005
;
24
:
1533
41
.
56.
Wang
Q
,
Diskin
S
,
Rappaport
E
,
Attiyeh
E
,
Mosse
Y
,
Shue
D
, et al
Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number
.
Cancer Res
2006
;
66
:
6050
62
.
57.
Wang
C
,
Liu
Z
,
Woo
CW
,
Li
Z
,
Wang
L
,
Wei
JS
, et al
EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR
.
Cancer Res
2012
;
72
:
315
24
.
58.
Stallings
RL
,
Howard
J
,
Dunlop
A
,
Mullarkey
M
,
McDermott
M
,
Breatnach
F
, et al
Are gains of chromosomal regions 7q and 11p important abnormalities in neuroblastoma?
Cancer Genet Cytogenet
2003
;
140
:
133
7
.
59.
Ochiai
H
,
Takenobu
H
,
Nakagawa
A
,
Yamaguchi
Y
,
Kimura
M
,
Ohira
M
, et al
Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bbeta and TSLC1 in neuroblastoma
.
Oncogene
2010
;
29
:
2681
90
.
60.
Cui
H
,
Ma
J
,
Ding
J
,
Li
T
,
Alam
G
,
Ding
HF
. 
Bmi-1 regulates the differentiation and clonogenic self-renewal of I-type neuroblastoma cells in a concentration-dependent manner
.
J Biol Chem
2006
;
281
:
34696
704
.
61.
Schulte
JH
,
Lim
S
,
Schramm
A
,
Friedrichs
N
,
Koster
J
,
Versteeg
R
, et al
Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy
.
Cancer Res
2009
;
69
:
2065
71
.
62.
Carén
H
,
Djos
A
,
Nethander
M
,
Sjöberg
RM
,
Kogner
P
,
Enström
C
, et al
Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma
.
BMC Cancer
2011
;
11
:
66
.
63.
Fujita
T
,
Igarashi
J
,
Okawa
ER
,
Gotoh
T
,
Manne
J
,
Kolla
V
, et al
CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas
.
J Natl Cancer Inst
2008
;
100
:
940
9
.
64.
Alaminos
M
,
Davalos
V
,
Cheung
NK
,
Gerald
WL
,
Esteller
M
. 
Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma
.
J Natl Cancer Inst
2004
;
96
:
1208
19
.
65.
Yang
Q
,
Kiernan
CM
,
Tian
Y
,
Salwen
HR
,
Chlenski
A
,
Brumback
BA
, et al
Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome
.
Clin Cancer Res
2007
;
13
:
3191
7
.
66.
Hoebeeck
J
,
Michels
E
,
Pattyn
F
,
Combaret
V
,
Vermeulen
J
,
Yigit
N
, et al
Aberrant methylation of candidate tumor suppressor genes in neuroblastoma
.
Cancer Lett
2009
;
273
:
336
46
.
67.
Grau
E
,
Martinez
F
,
Orellana
C
,
Canete
A
,
Yañez
Y
,
Oltra
S
, et al
Hypermethylation of apoptotic genes as independent prognostic factor in neuroblastoma disease
.
Mol Carcinog
2011
;
50
:
153
62
.
68.
Buckley
PG
,
Das
S
,
Bryan
K
,
Watters
KM
,
Alcock
L
,
Koster
J
, et al
Genome-wide DNA methylation analysis of neuroblastic tumors reveals clinically relevant epigenetic events and large-scale epigenomic alterations localized to telomeric regions
.
Int J Cancer
2011
;
128
:
2296
305
.
69.
Cotterman
R
,
Jin
VX
,
Krig
SR
,
Lemen
JM
,
Wey
A
,
Farnham
PJ
, et al
N-Myc regulates a widespread euchromatic program in the human genome partially independent of its role as a classical transcription factor
.
Cancer Res
2008
;
68
:
9654
62
.
70.
Teitz
T
,
Wei
T
,
Valentine
MB
,
Vanin
EF
,
Grenet
J
,
Valentine
VA
, et al
Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN
.
Nat Med
2000
;
6
:
529
35
.
71.
Murphy
DM
,
Buckley
PG
,
Bryan
K
,
Das
S
,
Alcock
L
,
Foley
NH
, et al
Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation
.
PLoS ONE
2009
;
4
:
e8154
.
72.
Angrisano
T
,
Sacchetti
S
,
Natale
F
,
Cerrato
A
,
Pero
R
,
Keller
S
, et al
Chromatin and DNA methylation dynamics during retinoic acid-induced RET gene transcriptional activation in neuroblastoma cells
.
Nucleic Acids Res
2011
;
39
:
1993
2006
.
73.
Coffey
DC
,
Kutko
MC
,
Glick
RD
,
Butler
LM
,
Heller
G
,
Rifkind
RA
, et al
The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid
.
Cancer Res
2001
;
61
:
3591
4
.
74.
De los Santos
M
,
Zambrano
A
,
Aranda
A
. 
Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SH-SY5Y cells
.
Mol Cancer Ther
2007
;
6
:
1425
32
.
75.
Zuber
J
,
Shi
J
,
Wang
E
,
Rappaport
AR
,
Herrmann
H
,
Sison
EA
, et al
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
.
Nature
2011
;
478
:
524
8
.
76.
de Bont
JM
,
Packer
RJ
,
Michiels
EM
,
den Boer
ML
,
Pieters
R
. 
Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective
.
Neuro-oncol
2008
;
10
:
1040
60
.
77.
Crea
F
,
Hurt
EM
,
Farrar
WL
. 
Clinical significance of Polycomb gene expression in brain tumors
.
Mol Cancer
2010
;
9
:
265
.
78.
Zakrzewska
M
,
Zakrzewski
K
,
Grešner
SM
,
Piaskowski
S
,
Zalewska-Szewczyk
B
,
Liberski
PP
. 
Polycomb genes expression as a predictor of poor clinical outcome in children with medulloblastoma
.
Childs Nerv Syst
2011
;
27
:
79
86
.
79.
Northcott
PA
,
Nakahara
Y
,
Wu
X
,
Feuk
L
,
Ellison
DW
,
Croul
S
, et al
Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma
.
Nat Genet
2009
;
41
:
465
72
.
80.
Yan
H
,
Parsons
DW
,
Jin
G
,
McLendon
R
,
Rasheed
BA
,
Yuan
W
, et al
IDH1 and IDH2 mutations in gliomas
.
N Engl J Med
2009
;
360
:
765
73
.
81.
Xu
W
,
Yang
H
,
Liu
Y
,
Yang
Y
,
Wang
P
,
Kim
SH
, et al
Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of a-ketoglutarate-dependent dioxygenases
.
Cancer Cell
2011
;
19
:
17
30
.
82.
Noushmehr
H
,
Weisenberger
DJ
,
Diefes
K
,
Phillips
HS
,
Pujara
K
,
Berman
BP
, et al
Cancer Genome Atlas Research Network
. 
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma
.
Cancer Cell
2010
;
17
:
510
22
.
83.
Fukuzawa
R
,
Reeve
AE
. 
Molecular pathology and epidemiology of nephrogenic rests and Wilms tumors
.
J Pediatr Hematol Oncol
2007
;
29
:
589
94
.
84.
Aiden
AP
,
Rivera
MN
,
Rheinbay
E
,
Ku
M
,
Coffman
EJ
,
Truong
TT
, et al
Wilms tumor chromatin profiles highlight stem cell properties and a renal developmental network
.
Cell Stem Cell
2010
;
6
:
591
602
.
85.
McEvoy
J
,
Flores-Otero
J
,
Zhang
J
,
Nemeth
K
,
Brennan
R
,
Bradley
C
, et al
Coexpression of normally incompatible developmental pathways in retinoblastoma genesis
.
Cancer Cell
2011
;
20
:
260
75
.
86.
Baylin
SB
,
Jones
PA
. 
A decade of exploring the cancer epigenome—biological and translational implications
.
Nat Rev Cancer
2011
;
11
:
726
34
.
87.
Matthay
KK
,
George
RE
,
Yu
AL
. 
Promising therapeutic targets in neuroblastoma
.
Clin Cancer Res
2012
;
18
:
2740
53
.
88.
George
RE
,
Lahti
JM
,
Adamson
PC
,
Zhu
K
,
Finkelstein
D
,
Ingle
AM
, et al
Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study
.
Pediatr Blood Cancer
2010
;
55
:
629
38
.
89.
Pinto
N
,
Cohn
SL
,
Dolan
ME
. 
Using germline genomics to individualize pediatric cancer treatments
.
Clin Cancer Res
2012
;
18
:
2791
800
.
90.
Piekarz
RL
,
Bates
SE
. 
Epigenetic modifiers: basic understanding and clinical development
.
Clin Cancer Res
2009
;
15
:
3918
26
.
91.
Mossman
D
,
Scott
RJ
. 
Long term transcriptional reactivation of epigenetically silenced genes in colorectal cancer cells requires DNA hypomethylation and histone acetylation
.
PLoS ONE
2011
;
6
:
e23127
.
92.
Juergens
RA
,
Wrangle
J
,
Vendetti
FP
,
Murphy
SC
,
Zhao
M
,
Coleman
B
, et al
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer
.
Cancer Discovery
2011
;
1
:
598
607
.
93.
Tsai
HC
,
Li
H
,
Van Neste
L
,
Cai
Y
,
Robert
C
,
Rassool
FV
, et al
Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells
.
Cancer Cell
2012
;
21
:
430
46
.
94.
McKenna
ES
,
Roberts
CW
. 
Epigenetics and cancer without genomic instability
.
Cell Cycle
2009
;
8
:
23
6
.
95.
Bradner
JE
,
West
N
,
Grachan
ML
,
Greenberg
EF
,
Haggarty
SJ
,
Warnow
T
, et al
Chemical phylogenetics of histone deacetylases
.
Nat Chem Biol
2010
;
6
:
238
43
.
96.
Fouladi
M
,
Park
JR
,
Stewart
CF
,
Gilbertson
RJ
,
Schaiquevich
P
,
Sun
J
, et al
Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report
.
J Clin Oncol
2010
;
28
:
3623
9
.
97.
Fouladi
M
,
Furman
WL
,
Chin
T
,
Freeman
BB
 3rd
,
Dudkin
L
,
Stewart
CF
, et al
Children's Oncology Group
. 
Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report
.
J Clin Oncol
2006
;
24
:
3678
85
.
98.
Su
JM
,
Li
XN
,
Thompson
P
,
Ou
CN
,
Ingle
AM
,
Russell
H
, et al
Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report
.
Clin Cancer Res
2011
;
17
:
589
97
.
99.
Balasubramanian
S
,
Ramos
J
,
Luo
W
,
Sirisawad
M
,
Verner
E
,
Buggy
JJ
. 
A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas
.
Leukemia
2008
;
22
:
1026
34
.
100.
Delmore
JE
,
Issa
GC
,
Lemieux
ME
,
Rahl
PB
,
Shi
J
,
Jacobs
HM
, et al
BET bromodomain inhibition as a therapeutic strategy to target c-Myc
.
Cell
2011
;
146
:
904
17
.
101.
Copeland
R
. 
Protein methyltransferases as a target class for cancer drug discovery [abstract]
.
In:
Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research
;
2011 April 2–6; Orlando, FL. Philadelphia (PA): AACR
; 
2011
.
Abstract nr SY08-01
.
102.
Tan
J
,
Yang
X
,
Zhuang
L
,
Jiang
X
,
Chen
W
,
Lee
PL
, et al
Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells
.
Genes Dev
2007
;
21
:
1050
63
.
103.
Miranda
TB
,
Cortez
CC
,
Yoo
CB
,
Liang
G
,
Abe
M
,
Kelly
TK
, et al
DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation
.
Mol Cancer Ther
2009
;
8
:
1579
88
.
104.
Daigle
SR
,
Olhava
EJ
,
Therkelsen
CA
,
Majer
CR
,
Sneeringer
CJ
,
Song
J
, et al
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor
.
Cancer Cell
2011
;
20
:
53
65
.
105.
Huang
Y
,
Greene
E
,
Murray Stewart
T
,
Goodwin
AC
,
Baylin
SB
,
Woster
PM
, et al
Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes
.
Proc Natl Acad Sci U S A
2007
;
104
:
8023
8
.